TABLE 1.
MRE clearance after beta-lactam (piperacillin-tazobactam or meropenem) administration
| Beta-lactam(s)a | Susceptibilityb | MRE clearance rate (no./total no. [%])c | Significanced |
|---|---|---|---|
| None | NA | 12/46 (26.1) | |
| PTZ and/or meropenem | S | 12/16 (75) | *** |
| PTZ and/or Meropenem | R/I | 4/14 (28.5) | NS |
| PTZ | S | 2/3 (66.6) | NS |
| PTZ | R/I | 4/10 (40) | NS |
| Meropenem | S | 10/13 (77) | * |
| Meropenem | R/I | 0/4 (0%) | NS |
a
Beta-lactam(s) that was administered between a pair of samples. PTZ, piperacillin-tazobactam.
b
Susceptibility of the MRE to the administered antibiotic. S, susceptible; R/I, nonsusceptible (resistant/intermediate phenotype); NA, not applicable.
c
Number of pairs of samples from the total analyzed in which the MRE was not detected in the second sample of the pair.
d
*, P < 0.05; ***, P < 0.001; NS, P > 0.05; Fischer test comparing with the group in which no beta-lactams were administered.